{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-009147","form_type":"8-K","ticker":"OVID","cik":"0001636651","company_name":"Ovid Therapeutics Inc.","filed_at":"2022-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.579556+00:00","generated_at":"2026-06-25T21:02:39.067717+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Takeda notifies Ovid of soticlestat Phase 3 delays; primary completion March 2024","bullets":["Takeda notified Ovid that two pivotal Phase 3 soticlestat trials (Dravet & Lennox-Gastaut) are likely delayed due to Ukraine/Russia and China COVID lockdowns.","Primary completion date now estimated March 2024; regulatory filings expected in Takeda's fiscal 2024.","Takeda stated studies remain highest-priority late-stage programs; actively recruiting with multiple approaches to minimize delays.","Ovid retains significant financial interest in soticlestat's development and potential commercialization."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-009147","json":"https://secwatch.observer/filing/0000950170-22-009147.json","markdown":"https://secwatch.observer/filing/0000950170-22-009147.md","text":"https://secwatch.observer/filing/0000950170-22-009147.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636651/000095017022009147/0000950170-22-009147-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636651/000095017022009147/ovid-20220510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:02:39.067717+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}